{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:41:34Z","timestamp":1777354894297,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Fibrinogen-like protein 2 (FGL2) is involved in immune-mediated inflammatory responses. However, its role in diarrhea-predominant irritable bowel syndrome (IBS-D) remains to be elucidated. This study investigated serum FGL2 levels in patients with IBS-D and examined their association with inflammatory cytokines, disease severity, and psychological status. Patients with inflammatory bowel disease (IBD), including Crohn\u2019s disease and ulcerative colitis, were excluded to avoid diagnostic overlaps. IBS-D diagnosis was based on the Rome III criteria.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 117 patients with IBS-D and 110 matched healthy controls were enrolled. Serum FGL2 and inflammatory cytokine levels (TNF-\u03b1, IL-1\u03b2, IL-6, and IL-17A) were quantified using ELISA. Symptom severity (IBS-SSS), depressive symptoms (PHQ-9), anxiety\/depression (HADS), and disease-specific quality of life (IBS-QOL) were assessed. In parallel, publicly available intestinal transcriptome datasets (GEO) were reanalyzed. Statistical analyses included Student\u2019s\n t-<\/jats:italic>\n test and Pearson\u2019s correlation.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Compared with healthy controls, patients with IBS-D exhibited significantly elevated serum FGL2, WBC, neutrophil, and pro-inflammatory cytokine levels (all\n P<\/jats:italic>\n &lt; 0.05). Serum FGL2 levels were markedly higher in patients with IBS-D and demonstrated a strong discriminative ability (AUC = 0.935; cutoff = 105.5 ng\/mL, sensitivity 82.9%, specificity 91.8%). FGL2 levels were positively correlated with TNF-\u03b1 (\n r<\/jats:italic>\n = 0.287), IL-1\u03b2 (\n r<\/jats:italic>\n = 0.338), IL-6 (\n r<\/jats:italic>\n = 0.251), and IL-17A (\n r<\/jats:italic>\n = 0.213). Higher FGL2 concentrations were also associated with increased symptom severity (IBS-SSS,\n r<\/jats:italic>\n = 0.241), greater depressive symptoms (PHQ-9,\n r<\/jats:italic>\n = 0.279), higher HADS scores (\n r<\/jats:italic>\n = 0.222), and poorer quality of life (IBS-QOL,\n r<\/jats:italic>\n = 0.198) (all\n P<\/jats:italic>\n &lt; 0.05). Transcriptomic reanalysis revealed dysregulation of FGL2 expression in IBS intestinal tissues, suggesting altered local immune regulation and a potential shift in the FGL2 isoform balance.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study provides the first evidence that serum FGL2 levels are elevated in IBS-D and are associated with inflammation, symptom severity, and psychological distress. While the correlations with immune and psychosocial measures are consistent with previous IBS research, the detection of FGL2 and the proposed isoform imbalance hypothesis represent novel findings. These results are exploratory, and causality cannot be inferred. Further validation and mechanistic studies are required.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1796532","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:57:04Z","timestamp":1777352224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum FGL2 is correlated with the severity and psychological status of diarrhea-predominant irritable bowel syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Fubing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nantong Second People\u2019s Hospital, Nantong","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nantong Second People\u2019s Hospital, Nantong","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Nantong Second Peoples Hospital, Nantong","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study.","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S2468-1253(21)00131-X","article-title":"Irritable bowel syndrome: a spotlight on future research needs.","volume":"6","author":"Black","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10.1111\/nmo.12982","DOI":"10.1111\/nmo.12982","article-title":"The impact of irritable bowel syndrome on daily functioning: characterizing and understanding daily consequences of IBS.","volume":"29","author":"Ballou","year":"2017","journal-title":"Neurogastroenterol Motil."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","article-title":"Global burden of irritable bowel syndrome: trends, predictions and risk factors.","volume":"17","author":"Black","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome.","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/jcm12072558","article-title":"Irritable bowel syndrome and the gut microbiome: a comprehensive review.","volume":"12","author":"Shaikh","year":"2023","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome-a systematic review.","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5056\/jnm16214","article-title":"What Is New in Rome IV.","volume":"23","author":"Schmulson","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/nmo.12358","article-title":"Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis.","volume":"26","author":"Bashashati","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1756284821993586","DOI":"10.1177\/1756284821993586","article-title":"Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review.","volume":"14","author":"Hanning","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.cell.2020.08.007","article-title":"Longitudinal Multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome.","volume":"182","author":"Mars","year":"2020","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"109799","DOI":"10.1016\/j.intimp.2023.109799","article-title":"Fibrinogen-like protein 2 in inflammatory diseases: a future therapeutic target.","volume":"116","author":"Fu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/ol.2020.12308","article-title":"Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment.","volume":"21","author":"Liu","year":"2021","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12879-018-3473-2","article-title":"Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases.","volume":"18","author":"Van Tong","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B15","first-page":"1629","article-title":"Fibrinogen-like protein 2 prothrombinase may contribute to the progression of inflammatory bowel disease by mediating immune coagulation.","volume":"11","author":"Dong","year":"2018","journal-title":"Int J Clin Exp Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-med-042320-014032","article-title":"The gut-brain axis.","volume":"73","author":"Mayer","year":"2022","journal-title":"Annu Rev Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5056\/jnm16135","article-title":"Biomarkers of irritable bowel syndrome.","volume":"23","author":"Kim","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.gtc.2025.08.002","article-title":"Biomarkers in Irritable Bowel Syndrome: rationale and Practical Use.","volume":"55","author":"Guan","year":"2026","journal-title":"Gastroenterol Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13189","DOI":"10.1111\/nmo.13189","article-title":"Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study.","volume":"30","author":"Vork","year":"2018","journal-title":"Neurogastroenterol Motil."},{"key":"B20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cgh.2019.10.004","article-title":"Benefits and pitfalls of change from Rome III to Rome IV criteria for irritable bowel syndrome and fecal incontinence.","volume":"18","author":"Lin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B22","unstructured":"Blighe\n K\n \n \n Rana\n S\n \n \n Lewis\n M.\n \n \n EnhancedVolcano: Publication-Ready Volcano Plots with Enhanced Colouring and Labeling. R package version 1.14.0.\n \n 2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/JIR.S499613","article-title":"Omentin-1, a Protective Adipokine for irritable bowel syndrome.","volume":"18","author":"Gao","year":"2025","journal-title":"J Inflamm Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13030-017-0092-x","article-title":"Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.","volume":"11","author":"Ida","year":"2017","journal-title":"Biopsychosoc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e76158","DOI":"10.7759\/cureus.76158","article-title":"Assessing the impact of irritable bowel syndrome on quality of life in patients at family medicine and primary health care clinics of the National Guard health affairs, Riyadh.","volume":"16","author":"AlDosari","year":"2024","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12888-021-03661-w","article-title":"The validity and reliability of the PHQ-9 on screening of depression in neurology: a cross sectional study.","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.11606\/s1518-8787.2025059006420","article-title":"Psychometric study of the Hospital Anxiety and Depression Scale with health professionals.","volume":"59","author":"Lopes","year":"2025","journal-title":"Rev Saude Publica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2022088","DOI":"10.4178\/epih.e2022088","article-title":"The clinical meaning of the area under a receiver operating characteristic curve for the evaluation of the performance of disease markers.","volume":"44","author":"Parodi","year":"2022","journal-title":"Epidemiol Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","article-title":"Receiver operating characteristic curve: overview and practical use for clinicians.","volume":"75","author":"Nahm","year":"2022","journal-title":"Korean J Anesthesiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10620-024-08836-5","article-title":"Exploration of cytokines and microbiome among males and females with diarrhea-predominant irritable bowel syndrome.","volume":"70","author":"Chen","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1053\/j.gastro.2016.12.039","article-title":"Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis.","volume":"152","author":"Klem","year":"2017","journal-title":"Gastroenterology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s10620-025-09360-w","article-title":"The interplay between immunological status and gut microbial dysbiosis in the development of the symptoms of irritable bowel syndrome: a systematic review with meta-analysis.","volume":"71","author":"Ahmed","year":"2026","journal-title":"Dig Dis Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41577-022-00700-9","article-title":"Immune activation in irritable bowel syndrome: What is the evidence?","volume":"22","author":"Aguilera-Lizarraga","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e34349","DOI":"10.1016\/j.heliyon.2024.e34349","article-title":"FGL2 improves experimental colitis related to gut microbiota structure and bile acid metabolism by regulating macrophage autophagy and apoptosis.","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0024","DOI":"10.5041\/RMMJ.10209","article-title":"Role of Regulatory T Cells (Treg) and the treg effector molecule fibrinogen-like protein 2 in alloimmunity and autoimmunity.","volume":"6","author":"Chruscinski","year":"2015","journal-title":"Rambam Maimonides Med J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"110468","DOI":"10.1016\/j.biopha.2020.110468","article-title":"Fibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization.","volume":"130","author":"Wu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2018.07.011","article-title":"Rome foundation working team report on post-infection irritable bowel syndrome.","volume":"156","author":"Barbara","year":"2019","journal-title":"Gastroenterology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1695321","DOI":"10.3389\/fimmu.2025.1695321","article-title":"Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B39","first-page":"539","article-title":"Immune activation in functional gastrointestinal disorders.","volume":"15","author":"Burns","year":"2019","journal-title":"Gastroenterol Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/ibd\/izz322","article-title":"Systemic inflammatory protein profiles distinguish irritable bowel syndrome (IBS) and ulcerative colitis, irrespective of inflammation or IBS-like symptoms.","volume":"26","author":"Moraes","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.12998\/wjcc.v12.i17.3094","article-title":"Immune cell signatures and causal association with irritable bowel syndrome: a mendelian randomization study.","volume":"12","author":"Chai","year":"2024","journal-title":"World J Clin Cases"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4520019","DOI":"10.1155\/jnme\/4520019","article-title":"Pathophysiological mechanisms and nonpharmacological interventions in irritable bowel syndrome: current insights and future directions.","volume":"2026","author":"Cheung","year":"2026","journal-title":"J Nutr Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2263209","DOI":"10.1080\/19490976.2023.2263209","article-title":"Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships.","volume":"15","author":"Yuan","year":"2023","journal-title":"Gut Microbes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01261","DOI":"10.1002\/brb3.1261","article-title":"Serum soluble fibrinogen-like protein 2 concentration predicts delirium after acute pancreatitis.","volume":"9","author":"Xu","year":"2019","journal-title":"Brain Behav"},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrgastro.2016.200","article-title":"Gut-brain axis in 2016: brain-gut-microbiota axis - mood, metabolism and behaviour.","volume":"14","author":"Dinan","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1796532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:57:13Z","timestamp":1777352233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1796532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":45,"alternative-id":["10.3389\/fmed.2026.1796532"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1796532","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1796532"}}